Marwan N Sabbagh1. 1. The Cleo Roberts Center for Clinical Research, Banner-Sun Health Research Institute, Sun City, AZ 85351, USA. Marwan.sabbagh@bannerhealth.com
Abstract
OBJECTIVE: The aim of this article was to provide a survey of the clinical development of pharmacotherapy for Alzheimer's disease (AD). METHODS: A search of PubMed to identify pertinent English-language literature was conducted using the terms Alzheimer's disease AND clinical trials (2003-2008), dementia AND prevention AND clinical trials (2003-2008), and the chemical names of all compounds mentioned in articles on new drugs for AD published since 2005. www.ClinicalTrials.gov was searched for relevant trials. Abstracts of the 2008 International Conference on Alzheimer's Disease (ICAD) were reviewed for relevance, as were pharmaceutical company and AD advocacy Web sites. Articles selected for review were primary reports of data from preclinical studies and clinical trials. RESULTS: A large number of drugs with differing targets and mechanisms of action are under development for the treatment of AD. Phase III trials of Ginkgo biloba, NSAIDs, phenserine, statins, tarenflurbil, tramiprosate, and xaliproden have been completed, none of them demonstrating adequate efficacy. Encouraging results from completed Phase II trials of dimebon, huperzine A, intravenous immunoglobulin, and methylthioninium chloride were reported at ICAD 2008. Nineteen compounds are currently in Phase II trials, and 3 compounds (AN1792, lecozotan SR, and SGS742) failed at this stage of development. CONCLUSIONS: Despite disappointing results from recently completed Phase III trials of several novel compounds, the extent and breadth of activity at all phases of clinical development suggest that new pharmacotherapeutic options for the treatment of AD will become available within the next decade.
OBJECTIVE: The aim of this article was to provide a survey of the clinical development of pharmacotherapy for Alzheimer's disease (AD). METHODS: A search of PubMed to identify pertinent English-language literature was conducted using the terms Alzheimer's disease AND clinical trials (2003-2008), dementia AND prevention AND clinical trials (2003-2008), and the chemical names of all compounds mentioned in articles on new drugs for AD published since 2005. www.ClinicalTrials.gov was searched for relevant trials. Abstracts of the 2008 International Conference on Alzheimer's Disease (ICAD) were reviewed for relevance, as were pharmaceutical company and AD advocacy Web sites. Articles selected for review were primary reports of data from preclinical studies and clinical trials. RESULTS: A large number of drugs with differing targets and mechanisms of action are under development for the treatment of AD. Phase III trials of Ginkgo biloba, NSAIDs, phenserine, statins, tarenflurbil, tramiprosate, and xaliproden have been completed, none of them demonstrating adequate efficacy. Encouraging results from completed Phase II trials of dimebon, huperzine A, intravenous immunoglobulin, and methylthioninium chloride were reported at ICAD 2008. Nineteen compounds are currently in Phase II trials, and 3 compounds (AN1792, lecozotan SR, and SGS742) failed at this stage of development. CONCLUSIONS: Despite disappointing results from recently completed Phase III trials of several novel compounds, the extent and breadth of activity at all phases of clinical development suggest that new pharmacotherapeutic options for the treatment of AD will become available within the next decade.
Authors: Nicola Origlia; Massimo Righi; Simona Capsoni; Antonino Cattaneo; Fang Fang; David M Stern; John Xi Chen; Ann Marie Schmidt; Ottavio Arancio; Shi Du Yan; Luciano Domenici Journal: J Neurosci Date: 2008-03-26 Impact factor: 6.167
Authors: G P Lim; F Yang; T Chu; P Chen; W Beech; B Teter; T Tran; O Ubeda; K H Ashe; S A Frautschy; G M Cole Journal: J Neurosci Date: 2000-08-01 Impact factor: 6.167
Authors: Sergey O Bachurin; Elena P Shevtsova; Elena G Kireeva; Gregory F Oxenkrug; Sergey O Sablin Journal: Ann N Y Acad Sci Date: 2003-05 Impact factor: 5.691
Authors: C G Lyketsos; J C S Breitner; R C Green; B K Martin; C Meinert; S Piantadosi; M Sabbagh Journal: Neurology Date: 2007-04-25 Impact factor: 9.910
Authors: Ahmadul Kadir; Niels Andreasen; Ove Almkvist; Anders Wall; Anton Forsberg; Henry Engler; Göran Hagman; Marie Lärksäter; Bengt Winblad; Henrik Zetterberg; Kaj Blennow; Bengt Långström; Agneta Nordberg Journal: Ann Neurol Date: 2008-05 Impact factor: 10.422
Authors: Joan Lindsay; Danielle Laurin; René Verreault; Réjean Hébert; Barbara Helliwell; Gerry B Hill; Ian McDowell Journal: Am J Epidemiol Date: 2002-09-01 Impact factor: 4.897
Authors: Joseph A McQuail; Cristina Bañuelos; Candi L LaSarge; Michelle M Nicolle; Jennifer L Bizon Journal: Neurobiol Aging Date: 2011-12-14 Impact factor: 4.673
Authors: Joshua D Grill; Lijie Di; Po H Lu; Cathy Lee; John Ringman; Liana G Apostolova; Nicole Chow; Omid Kohannim; Jeffrey L Cummings; Paul M Thompson; David Elashoff Journal: Neurobiol Aging Date: 2012-04-13 Impact factor: 4.673